| Backgroud: Renal cell carcinoma(RCC)is one of the most common urological tumors with high morbidity and mortality,and is a malignant tumor with poor prognosis.Renal clear cell carcinoma(ccRCC)accounts for about 80-90%.Many patients with ccRCC have been advanced at the initial diagnosis,and 20-30% of them may have postoperative recurrence and metastasis.Treatment of advanced ccRCC is limited,and the main reason for its poor efficacy is its insensitivity to adjuvant therapies,such as radiotherapy and chemotherapy.At present,ccRCC is mainly treated with anti-angiogenesis targeted drugs,but it has great toxic and side effects and it is effective in a small number of patients,and most patients develop drug resistance to varying degrees,which brings great difficulties to the treatment of advanced RCC.Current studies have found that glycolysis plays an important role in the occurrence and development of tumors,and the search for enzymes that play an important role in the metabolic pathway of glycolysis is of great significance for the treatment of RCC.Methods:1.Based on Oncomine database to analyze the expression level and difference of ALDOA gene in 94 cases of renal clear cell carcinoma and 50 normal kidney tissues;2.Retrospective analysis of 74 patients with renal clear cell carcinoma who underwent surgery in Hunan Provincial people's hospital from 2011 to 2015,The expression ofALDOA in 74 cases of renal clear cell carcinoma was detected by immunohistochemical SP method.The relationship between ALODA expression and clinical pathological features and prognosis of ccRCC patients was analyzed.the results were analyzed with SPSS20.0 software,P <0.05 was regarded as statistically significant critical value.Results:There are 5 datasets of the Oncomine database in meta analysis,including a total of 144 samples,94 cases of renal clear cell carcinoma and 50 cases of normal renal tissues.The results showed that the ALDOA gene was highly expressed in ccRCC compared with normal kidney tissue(P <0.01).The complete clinical pathological parameters and follow-up data of 74 patients were retrospectively analyzed.The median follow-up time was 43 months and the longest was 92 months.During the follow-up,17 patients(22.9%)were found to have recurrence and 2(2.7%)died.41(55.4%)patients in the ALDOA high expression group and 33 patients(44.6%)in the low expression group.There was a positive correlation between ALDOA expression level and tumor diameter ?7cm(P <0.05),advanced pT stage(P <0.05),renal capsule invasion(P<0.05),and recurrence and metastasis(P<0.05).Kaplan-Meier was used.Analysis and Log-rank log-rank test showed a negative correlation between ALODA expression and progression-free survival(PFS)(P<0.05).Univariate COX proportional hazard regression analysis showed that late pT stage,diameter ?7cm,invasion of capsule,highFuhrman grade,high ALDOA expression was negatively correlated with PFS(P<0.05).Multivariate COX proportional hazard regression analysis showed that high ALDOA expression and advanced pT stage were independent prognostic factors for renal cell carcinoma(P<0.05).Conclusion:1.Bioinformatics data mining based on Oncomine and other databases is more convenient and comprehensive for screening diagnostic and prognostic novel biomarkers.It has strong evidence.2.High expression of ALDOA in ccRCC provides a theoretical basis for ALDOA for early clinical screening of ccRCC.It is positively correlated with tumor diameter,renal capsule invasion and advanced pT stage;3.High ALODA expression is negatively correlated with disease progression-free survival(PFS)rate in ccRCC patients.It is a PFS independent prognostic factor for ccRCC. |
PDF Full Text Request